Loading…

Tokai Corp.9729.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Services to the Health Industry
Momentum leader 81
Mkt cap
$559M
US dollars, full cap
Free float
52%
of shares outstanding
$/day
$1.16M
20-day average traded
Fwd P/E
12.7×
forward earnings
ROIC−WACC
+5.3 pp
WACC 5.0%
Hurdle
-20 pp
Req g minus delivered
Next earnings
79 days
5 Feb 2027
Close · JPY¥2,756
1D-0.8%
1W+1.2%
1M+3.4%
3M+8.3%
6M+12.8%
YTD+9.7%
1Y+27.4%
ATR %3.2%
52w lowhigh7.9% off high

What Tokai does

Employees: 4,694

Tokai at a glance

Size Tokai (9729.T) is a Japan Health Care company (Services to the Health Industry) with a market value of $559M, the 1006th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,756 on 18 Nov 2026.

Performance Over six months the shares gained 12.8%, against +34.0% for the median peer and -1.4% for the Japan market (cap-weighted) — 2nd lowest of 6 in its peer set.

Growth Revenue grew 4.4% over the last twelve months (peer median +9.1%); the operating margin is 6.1% (peer median 11.1%).

Valuation It trades at 12.7× forward earnings against a peer median of 22.4× (cheapest of 6).

Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -20 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 5.3 points above its cost of capital (5.0% WACC).

Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 1349729.T 114
Six months, rebased to 100: Tokai against the median of its 5 peers (local-currency closes).

Tokai financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥163B¥160B¥150B¥138B¥130B
Revenue growth—+7%+8%+6%—
Gross profit¥40.2B¥38.8B¥35.4B¥33.6B¥31.9B
EBITDA¥14.8B¥14.5B¥13.3B¥12.8B¥11.9B
Net income¥6.37B¥6.07B¥4.73B¥5.81B¥6.11B
Free cash flown/a¥8.15B¥5.99B-¥372M¥2.94B
Capital expendituren/a¥4.07B¥4.76B¥8.70B¥6.22B
Total debt¥2.77B¥3.48B¥2.63B¥2.35B¥2.87B

Quarterly statements and history in the cockpit →

Tokai competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-20%0%+20%NRCASTHATTPMEDGX9729.T6-month return →1-month return →
Up and to the right = strong over both horizons. Tokai is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%50×100×NRCASTHATTPMEDGX9729.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tokai is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%NRCASTHATTPMEDGX9729.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Tokai is the large dot.

Tokai competitors and peer comparison

How Tokai compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tokai against its 5 peers (data as of 18 Nov 2026)
Measure9729.TPeer medianRank in peer set
1-month return+3.4%+9.5%2nd lowest of 6
6-month return+12.8%+34.0%2nd lowest of 6
Distance from 52-week high-7.9%-5.2%3rd lowest of 6
Revenue growth (TTM)+4.4%+9.1%3rd lowest of 6
Operating margin6.1%11.1%2nd lowest of 6
Forward P/E12.7×22.4×cheapest of 6
Growth the price implies (Req g, 7 yrs)-13.4%7.4%least demanding of 6
Growth delivered (Del g)+6.2%+9.1%3rd lowest of 6
Hurdle (Req g minus delivered)-19.7 pp+4.0 pp2nd least demanding of 6
ROIC minus cost of capital+5.3 pp+2.5 pp3rd highest of 6
EV / EBITDA4.6×20.8×cheapest of 5
Net debt / EBITDA-1.5×3.1×least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Tokai 9729.TJapan$559M+13%+4%6%12.7×-13.4%+6.2%
NRC Health NRCUnited States$555M+36%+3%11%26.4×11.2%+0.6%
Astrana Health ASTHUnited States$1.47B-24%+35%3%17.6×7.4%+35.9%
Attendo ATT.STSweden$1.87B+15%0%10%16.9×1.7%+9.1%
Pro Medicus PME.AXAustralia$13.4B+52%+23%75%105.7×53.5%+31.0%
Quest Diagnostics DGXUnited States$28.6B+34%+9%15%22.4×7.2%+3.2%

Questions

Which companies are Tokai's closest peers?
The cockpit's peer set: NRC Health (NRC), Astrana Health (ASTH), Attendo (ATT.ST), Pro Medicus (PME.AX), Quest Diagnostics (DGX).
Is Tokai expensive compared with its peers?
On forward p/e it trades at 12.7× against a peer median of 22.4×, cheapest of 6 in its peer set. For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -20 pp: the price already allows for a slowdown.
How has Tokai stock performed?
Over six months to 18 Nov 2026 the shares returned +12.8% against +34.0% for the median peer; over one year +27.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.